Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

Blood

Volumn 118, Issue 17, 2011, Pages 4690-4693

  Naqvi, Kiran ^a   Jabbour, Elias ^a   Bueso Ramos, Carlos ^a   Pierce, Sherry ^a   Borthakur, Gautam ^a   Estrov, Zeev ^a   Ravandi, Farhad ^a   Faderl, Stefan ^a   Kantarjian, Hagop ^a   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; DIAGNOSTIC PROCEDURE; FEMALE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MYELOBLAST; MYELODYSPLASTIC SYNDROME; PATIENT REFERRAL; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SIDEROBLASTIC ANEMIA; TERTIARY HEALTH CARE;

EID: 80055067019     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-342642     Document Type: Article

References (10)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19):1872-1885.
2. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 2011;29(5):516-523.
3. DeLima M, Albitar M, O'Brien S, et al. Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia. Am J Med. 1998;104(3):246-251. (Pubitemid 28163169)
4. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
5. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199. (Pubitemid 12073508)
6. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. (Pubitemid 27132124)
7. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440. (Pubitemid 34525728)
8. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
9. Kantarjian H, Issa J-P, Rosenfield C, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer. 2006;106:1794-1803.
10. Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93(11):1712-1717.